Drug Safety Analysis in a Real-Life Cohort of Parkinson's Disease Patients with Polypharmacy
| Autor: | Saskia Müller-Rebstein, Günter U. Höglinger, Carsten Culmsee, Claudia Trenkwalder, Jens Ebentheuer, Wolfgang H. Oertel |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Parkinson's disease administration & dosage [Antiparkinson Agents] Comorbidity Pharmacology 030226 pharmacology & pharmacy Antiparkinson Agents Cohort Studies 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Risk Factors Internal medicine adverse effects [Antiparkinson Agents] Medicine Humans Pharmacology (medical) Drug Interactions ddc:610 Prospective Studies Medical prescription Prospective cohort study Aged Polypharmacy business.industry Parkinson Disease Middle Aged medicine.disease drug therapy [Parkinson Disease] Hospitalization Psychiatry and Mental health Cohort Drug Therapy Combination Female Neurology (clinical) business 030217 neurology & neurosurgery Cohort study |
| Zdroj: | CNS drugs 31(12), 1093-1102 (2017). doi:10.1007/s40263-017-0478-0 |
| ISSN: | 1179-1934 |
| DOI: | 10.1007/s40263-017-0478-0 |
| Popis: | Polypharmacy is common in geriatric Parkinson’s disease (PD) patients in advanced disease stages with multiple comorbidities, bearing multiple risks for drug safety in theory. The aim of this study was to empirically identify the most frequent and relevant contraindications and drug interactions actually occurring and compromising drug safety in PD in real life. We conducted a prospective observational study in a multimorbid cohort of PD patients with polypharmacy admitted to a specialized hospital. Inclusion criteria were the presence of at least one comorbidity requiring pharmacotherapy and at least five different drugs in the discharge prescription. Hoehn and Yahr stage during the ‘on’ state, therapeutic problems related to motor and non-motor PD symptoms, comorbidities, and drug regimens on admission and discharge were analyzed for contraindications and interactions. Overall, 127 patients were included (medium Hoehn and Yahr stage = IV, range II–V). Interactions with the anti-PD medication were mainly caused by other central nervous system (CNS)-active substances, cytochrome P450-metabolized substances, and QT-time prolonging substances. Contraindications against the anti-PD medication mainly occurred from internal, haematopoietic, neurologic and psychiatric diseases, and QT-time prolonging drugs. The highest frequency of interactions and contraindications were identified with levodopa (n = 119 at admission/n = 126 at discharge), entacapone (n = 46/42), pramipexole (n = 44/24), and amantadine (n = 32/30). Several medically relevant risk factors (interactions and contraindications) frequently occurred in advanced PD patients. These findings provide a basis for developing programmes for awareness, education, monitoring, and preventive interventions to avoid adverse incidents. Future studies will need to evaluate preventive efficacy of structured drug safety programmes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink